{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:51:18Z","timestamp":1785765078816,"version":"3.56.0"},"reference-count":26,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Over the past decades, major advances have been achieved in the field of anticancer therapies, with several breakthroughs representing true milestones in cancer treatment [...]<\/jats:p>","DOI":"10.3390\/ijms27156942","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:57:56Z","timestamp":1785761876000},"page":"6942","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special Issue \u201cNovel Targeted Therapies and Drugs in Cancer\u201d"],"prefix":"10.3390","volume":"27","author":[{"given":"Maria Teresa","family":"Vietri","sequence":"first","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u201cLuigi Vanvitelli\u201d, Via L. De Crecchio, 7, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0092-8674(00)00043-X","article-title":"Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch","volume":"102","author":"Lei","year":"2000","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrc3645","article-title":"PAK signalling during the development and progression of cancer","volume":"14","author":"Radu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","first-page":"46","article-title":"PAK4 inhibition improves PD-1 blockade immunotherapy","volume":"1","author":"Torrejon","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9446","DOI":"10.1073\/pnas.0911863107","article-title":"Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth","volume":"107","author":"Murray","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41416-023-02523-4","article-title":"PAK inhibitor FRAX486 decreases the metastatic potential of triple-negative breast cancer cells by blocking autophagy","volume":"130","author":"Lyu","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2022008378","article-title":"Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome","volume":"7","author":"DiNardo","year":"2023","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"Fenaux","year":"2023","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Macarulla","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Doyle, L.M., and Wang, M.Z. (2019). Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis. Cells, 8.","DOI":"10.3390\/cells8070727"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"24641","DOI":"10.3402\/jev.v3.24641","article-title":"Routes and mechanisms of extracellular vesicle uptake","volume":"3","author":"Mulcahy","year":"2014","journal-title":"J. Extracell. Vesicles"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yu, J., Sane, S., Kim, J.E., Yun, S., Kim, H.J., Jo, K.B., Wright, J.P., Khoshdoozmasouleh, N., Lee, K., and Oh, H.T. (2023). Biogenesis and delivery of extracellular vesicles: Harnessing the power of EVs for diagnostics and therapeutics. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1330400"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"113816","DOI":"10.1016\/j.addr.2021.05.026","article-title":"Role of extracellular vesicles in liver diseases and their therapeutic potential","volume":"175","author":"Kostallari","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00018-022-04256-8","article-title":"Circulating cell-specific extracellular vesicles as biomarkers for the diagnosis and monitoring of chronic liver diseases","volume":"79","author":"Newman","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_18","first-page":"4809","article-title":"Chalcones against the hallmarks of cancer: A mini-review","volume":"36","author":"Melo","year":"2022","journal-title":"Nat. Prod. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7762","DOI":"10.1021\/acs.chemrev.7b00020","article-title":"Chalcone: A Privileged Structure in Medicinal Chemistry","volume":"117","author":"Zhuang","year":"2017","journal-title":"Chem. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ouyang, Y., Li, J., Chen, X., Fu, X., Sun, S., and Wu, Q. (2021). Chalcone Derivatives: Role in Anticancer Therapy. Biomolecules, 11.","DOI":"10.3390\/biom11060894"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1940-6207.CAPR-15-0338","article-title":"Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1\/FOXO1 Axis","volume":"9","author":"Jiang","year":"2016","journal-title":"Cancer Prev. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00018-019-03185-3","article-title":"Isorhapontigenin (ISO) inhibits stem cell-like properties and invasion of bladder cancer cell by attenuating CD44 expression","volume":"77","author":"Luo","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41419-022-05205-w","article-title":"Induction of RAC1 protein translation and MKK7\/JNK-dependent autophagy through dicer\/miR-145\/SOX2\/miR-365a axis contributes to isorhapontigenin (ISO) inhibition of human bladder cancer invasion","volume":"13","author":"Hua","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/335142a0","article-title":"The origin of mutants","volume":"335","author":"Cairns","year":"1988","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"M57","DOI":"10.1016\/S0962-8924(99)01661-X","article-title":"Genetic instability and darwinian selection in tumours","volume":"9","author":"Cahill","year":"1999","journal-title":"Trends Cell Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1073\/pnas.0334858100","article-title":"Multiple mutations and cancer","volume":"100","author":"Loeb","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6942\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:09:32Z","timestamp":1785762572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,2]]},"references-count":26,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27156942"],"URL":"https:\/\/doi.org\/10.3390\/ijms27156942","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,2]]}}}